Differential staining of γ synuclein in poorly differentiated compared to highly differentiated colon cancer cells

Oncology Reports

Volumn 27, Issue 5, 2012, Pages 1451-1454

  Amsterdam, Abraham ^a   Shezen, Elias ^a   Raanan, Calanit ^a   Schreiber, Letizia ^b   Slilat, Yasmin ^a   Fabrikant, Yakov ^c,d   Melzer, Ehud ^c,d  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b WOLFSON MEDICAL CENTER   (Israel)

^c KAPLAN MEDICAL CENTER   (Israel)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

synuclein; Cancer stem cells; Colon cancer; Differentiated and non differentiated tumors

Indexed keywords

GAMMA SYNUCLEIN; PROTEIN ANTIBODY;

ADIPOSE TISSUE; ARTICLE; BLOOD VESSEL WALL; CANCER CELL; CELL DIFFERENTIATION; CELL LABELING; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LYMPH NODE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE DISTRIBUTION;

COLONIC NEOPLASMS; GAMMA-SYNUCLEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM GRADING; NEOPLASM STAGING;

EID: 84858202512     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1658     Document Type: Article

References (18)

1. Bruening W, Giasson BI, Klein-Szanto AJ, Lee VM, Trojanowski JQ and Godwin AK: Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. Cancer 88: 2154-2163, 2000. (Pubitemid 30233219)
2. Ye Q, Wang TF, Peng YF, Xie J, Feng B, Qiu MY, Li LH, Lu AG, Liu BY and Zheng MH: Expression of α, β and γ-synuclein in colorectal cancer, and potential clinical significance in progression of the disease. Oncol Rep 23: 429-436, 2010.
3. Lavedan C, Leroy E, Dehejia A, Buchholtz S, Dutra A, Nussbaum RL and Polymeropoulos MH: Identification, localization and characterization of the human γ-synuclein gene. Hum Genet 103: 106-112, 1998. (Pubitemid 28398395)
4. Singh VK and Jia Z: Targeting synuclein-γ to counteract drug resistance in cancer. Expert Opin Ther Targets 12: 59-68, 2008. (Pubitemid 351247162)
5. Ahmad M, Attoub S, Singh MN, Martin FL and El-Agnaf OM: γ-synuclein and the progression of cancer. FASEB J 21: 3419-3430, 2007.
6. Hu H, Sun L, Guo C, Liu Q, Zhou Z, Peng L, Pan J, Yu L, Lou J, Yang Z, Zhao P and Ran Y: Tumor cell-microenvironment interaction models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis. Clin Cancer Res 15: 5485-5493, 2009.
7. Pan ZZ, Bruening W, Giasson BI, Lee VM and Godwin AK: γ-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways. J Biol Chem 277: 35050-35060, 2002.
8. Shimoda T, Ikegami M, Fujisaki J, Matsui T, Aizawa S and Ishikawa E: Early colorectal carcinoma with special reference to its development de novo. Cancer 64: 1138-1146, 1989. (Pubitemid 19208871)
9. Czekierdowski A, Czekierdowska S, Wielgos M, Smolen A, Kaminski P and Kotarski J: The role of CpG islands hypomethylation and abnormal expression of neuronal protein synuclein-gamma (SNCG) in ovarian cancer. Neuro Endocrinol Lett 27: 381-386, 2006. (Pubitemid 44390076)
10. Liu H, Liu W, Wu Y, Zhou Y, Xue R, Luo C, Wang L, Zhao W, Jiang JD and Liu J: Loss of epigenetic control of synuclein-γ gene as a molecular indicator of metastasis in a wide range of human cancers. Cancer Res 65: 7635-7643, 2005. (Pubitemid 41297236)
11. Zeren T, Inan S, Seda Vatansever H, Ekerbicer N and Sayhan S: Significance of tyrosine kinase activity on malign transformation of ovarian tumors: a comparison between EGF-R and TGF alpha. Acta Histochem 110: 256-263, 2008. (Pubitemid 351626123)
12. Ginath S, Menczer J, Friedmann Y, Aingorn H, Aviv A, Tajima K, Dantes A, Glezerman M, Vlodavsky I and Amsterdam A: Expression of heparanase, Mdm2, and erbB2 in ovarian cancer. Int J Oncol 18: 1133-1144, 2001.
13. Singer G, Stöhr R, Cope L, et al: Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29: 218-224, 2005. (Pubitemid 40170640)
14. Shaikh AJ, Raza S, Shaikh AA, Idress R, Kumar S, Rasheed YA, Lal A and Masood N: Demographics, pathologic patterns and long-term survival in operable colon cancers: local experience in Pakistan. Asian Pac J Cancer Prev 10: 361-364, 2009.
15. Vogelstein B, Fearon ER, Hamilton SR, et al: Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532, 1988.
16. Medema JP and Vermeulen L: Microenvironmental regulation of stem cells in intestinal homeostasis and cancer. Nature 474: 318-326, 2011.
17. Todaro M, Francipane MG, Medema JP and Stassi G: Colon cancer stem cells: promise of targeted therapy. Gastroenterology 138: 2151-2162, 2010.
18. Zhang H, Maitta RW, Bhattacharyya PK, Florea AD, Sen F, Wang Q and Ratech H: γ-synuclein is a promising new marker for staining reactive follicular dendritic cells, follicular dendritic cell sarcoma, Kaposi sarcoma, and benign and malignant vascular tumors. Am J Surg Pathol 35: 1857-1865, 2011.